Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2017-12-08 Director's Dealing
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2017-12-08 English
PRIMARY DOCUMENT
Director's Dealing
2017-12-08 English
PRIMARY DOCUMENT
Director's Dealing
2017-12-08 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 4, 2017, reporting the entry into a material definitive agreement (a Commercialization Agreement) between Collegium Pharmaceutical, Inc. and Depomed, Inc. It details the terms of the agreement, including license fees, royalties, termination rights, and security interests. The document also includes a press release and an investor presentation as exhibits. There are no financial statements or quarterly/annual financial results presented. The content is focused on a material contract and related disclosures, typical of an 8-K current report. This is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-12-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2017. It reports an amendment to the company's bylaws regarding the election of directors, specifically changing the voting standard for non-contested director elections. The document includes a description of the amended and restated bylaws and references the company's corporate governance guidelines. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The content focuses on governance changes, specifically board-related rules and procedures. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management, including governance-related amendments affecting the board.
2017-12-02 English
PRIMARY DOCUMENT
Director's Dealing
2017-11-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.